Novo Nordisk after massive deal: We are still looking for acquisitions and license agreements

Novo Nordisk has purchased the rights for a drug against two rare blood disorders in a potential million dollar deal, but according to Executive Vice President and Chief Science Officer, Mads Krogsgaard Thomsen, Novo is still searching the market for external possibilities.

Photo: /ritzau scanpix/Claus Bech

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles